Heart Disease | Page 65 of 95

Heart Disease :: MEDAL – No increase in cardiovascular events with COX-2 inhibitor

Researchers in the randomized Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program found identical rates of thrombotic cardiovascular events in patients with osteoarthritis or rheumatoid arthritis treated with either the COX-2 inhibitor or the traditional NSAID. Christopher Cannon, M.D., an associate professor of medicine at Harvard Medical School, Boston, noted that this appears to contradict earlier observational studies associating COX-2 inhibitors with higher rates of thrombotic cardiovascular events.

Heart Disease :: WAFACS – Folic acid, B vitamins not supported

Results of a randomized trial of folic acid and B-vitamins in secondary prevention of cardiovascular events in women did not support their use as preventive agents against cardiovascular disease in women with established vascular disease or those at high risk.

Heart Disease :: CHICAGO study – Two blood sugar drugs evaluated

Another late-breaker presented here was the appropriately named CHICAGO Study, in which 462 patients with type 2 diabetes were randomly selected at Chicago heart clinics to receive treatment with pioglitazone or with glimepriride.

Heart Disease :: Framingham Study gives key insights on CVD risks

The Framingham Heart Study revolutionized how physicians approach cardiovascular disease (CVD) and placed prevention at the forefront of cardiology.

Heart Disease :: Stent wars ease into stent discussions

Acrimonious debate over the use of bare metal stents (BMS) versus drug-eluting stents (DES) is ending. Four new studies presented during a Monday news conference are quickly turning what had been open warfare between BMS and DES advocates into more measured discussions.

NIH director addresses medical research challenges

The greatest risk in science is to stop taking risks,? said Elias A. Zerhouni, Director of the National Institutes of Health (NIH), Bethesda, Md.

Heart Disease :: Anticoagulant-antidote combo safe in humans

A novel anticoagulant and its complementary antidote was proven safe in the first human trial, say researchers from Duke University Medical Center, Durham, N.C. The system could be valuable, holding promise that clinicians could titrate anticoagulation, as it may not require monitoring.

Heart Disease :: Arm exercises enhance walking distance in PAD

Patients with peripheral arterial disease (PAD) can benefit from upper-body aerobic exercises, according to a study presented at Scientific Sessions by Diane Treat-Jacobson, Ph.D., R.N., assistant professor at the University of Minnesota School of Nursing, Minneapolis. The findings of the study demonstrated significantly increased maximal walking distance and delayed onset of claudication after aerobic arm exercises.

Heart Disease :: PCI for occlusion after MI not always beneficial

Logic would hold that an occluded infarct-related artery should be open before the patient is discharged. But the chair of the Occluded Artery Trial (OAT) presented data here showing that stable patients undergoing routine PCI for occluded arteries three to 28 days after MI had virtually the same number of major cardiovascular events as similar patients receiving medication alone.

Heart Attack :: Late angioplasty after heart attack no better than drug therapy

About one-third of heart attack patients do not receive treatment to open blocked arteries within the recommended 12-hour timeframe after a heart attack. Treatment such as angioplasty or clot-busting drugs may not be given because patients arrive at the hospital too late.